Author

Dr. Nathan Pryce

Dr. Nathan Pryce covers the biotech industry for Dark Biotechnology: companies, pipelines, financing and FDA decisions, with endpoint results and dollar figures carrying their disclosure basis.

Articles by Dr. Nathan Pryce

An executive in a glass-walled office reviewing documents at a steel desk, laboratory equipment soft-focus behind cool white drapery of light.

Biotech News

What BioNTech's CEO Change Signals About Biotech Leadership Transitions

Dr. Nathan Pryce

Two analysts comparing printed abstract pages against a journal proof under the cold white light of a glass-walled meeting room.

Biotech News

Why a Conference Abstract Is Not a Publication: Reading Meeting Data With Caution

Dr. Nathan Pryce

A scientist in a white coat reviewing production data at a stainless bioreactor console under cool teal lighting.

Biotech News

Johnson & Johnson Lifts 2026 Outlook After $25.3 Billion Second Quarter

Dr. Nathan Pryce

A scientist in a white coat examining labeled bioreactor sample vials in a cold, glass-lined biologics quality-control lab.

Biotech News

Celltrion and Teva's Truxima Becomes First Interchangeable Rituximab Biosimilar in the US

Dr. Nathan Pryce

A scientist in safety glasses adjusts a bioreactor control panel, gloved hand on steel, cool white-teal light across glass vessels, no logos.

Biotech News

Parabilis Medicines Raises Record $670 Million Biotech IPO

Dr. Nathan Pryce

A laboratory technician pipettes clear reagent into a microplate at a white bench under cool teal task lighting.

Biotech News

FDA Approves Shionogi's Xocova as First Oral COVID-19 Post-Exposure Prophylaxis

Dr. Nathan Pryce